Marc Yoskowitz

Marc Yoskowitz brings deep leadership and management experience in the pharmaceutical industry to Keenova, which he served as Board Chair from September 2025 to May 2026. 

Mr. Yoskowitz has served on the Board of Directors at Mereo BioPharma since 2022, where he is a member of the R&D Committee, and previously held a Board position at Endo, Inc., where he chaired the compliance committee and sat on the nomination and governance committee and the product portfolio committee, from April 2024 to July 2025. Since January 2024, he has served as CEO and director of Evozyne, Inc., a venture capital–backed biotech designing novel proteins leveraging generative AI. 

Previously, he served as EVP and Chief Strategy Officer, Life Sciences, at Tempus AI, Inc. Prior to Tempus, Mr. Yoskowitz was Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development, at Hospira and was a member of the Executive Committee. 

Earlier in his career, Mr. Yoskowitz led business development at a specialty pharmaceutical company; spent eight years at McKinsey & Company, where he was an Associate Principal; and began his career as an M&A lawyer at Davis, Polk & Wardwell in New York. 

Mr. Yoskowitz received a bachelor’s degree magna cum laude from Washington University in St. Louis and holds a J.D. from Columbia University School of Law.